Annick De Weerdt

Dr. Annick De Weerdt


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2020 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
AWAnnick De Weerdt
Annick De Weerdt
BJBram G. Janssen
Bram G. Janssen
BCBianca Cox
Bianca Cox
EBEsmée M. Bijnens
Esmée M. Bijnens
CVCharlotte Vanpoucke
Charlotte Vanpoucke
PJPhilippe G. Jorens
Philippe G. Jorens

29 August 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AWAnnick De Weerdt
Annick De Weerdt
ADAmélie Dendooven
Amélie Dendooven
ASAnnemie Snoeckx
Annemie Snoeckx
JPJan Pen
Jan Pen
MLMartin Lammens
Martin Lammens
PJPhilippe G. Jorens
Philippe G. Jorens
The FOLFOX regimen, i.e., folinic acid (FOL), fluorouracil (F) and oxaliplatin (OX), is a drug cocktail that is used to treat gastric and colorectal cancers. Despite the concomitant improvements in response rate, duration of response and patient survival, reports of serious toxic pulmonary side effects have progressively emerged. We describe a patient who was treated with FOLFOX as an adjuvant to a rectosigmoidal resection of a rectosigmoidal carcinoma and who developed respiratory insufficiency requiring mechanical ventilation. Computed tomography (CT) imaging and open lung biopsy findings were compatible with interstitial pneumonia (IP). She received multimodal combination treatment (acetylcysteine, corticosteroids, immune globulins and cyclophosphamide) and survived. We performed a systematic literature search and reviewed all 45 reported cases of FOLFOX-related lung toxicity and/or pulmonary fibrosis for their clinical characteristics and their outcomes related to therapy. We found that for the 45 cases with available data, the median age was 70 years, and the male–female ratio was 3.5: 1. In the patients exhibiting only mild respiratory symptoms, discontinuation of the culprit drug (oxaliplatin) resulted in a 100% regression of the symptoms. However the prognosis of the respiratory insufficient patient proved to be grim: death occurred in 76.9% of the cases despite conventional treatment with corticosteroids. We therefore urge oncologists and critical care specialists not to limit their interventions to the discontinuation of chemotherapy, artificial ventilation, corticosteroids and glutathione replenishment and to consider the gradual introduction of additional immune-modulating agents whenever life-threatening respiratory symptoms in oxaliplatin-treated patients do not subside; all the more so considering the fact that our analysis showed that every patient who survived intubation and mechanical ventilation experienced a full clinical recovery.

28 February 2007 in Resuscitation
Verified
Journal Article
Closed access
CPChristine Pluymakers
Christine Pluymakers
AWAnnick De Weerdt
Annick De Weerdt
YJYves Jacquemyn
Yves Jacquemyn
CCCecile Colpaert
Cecile Colpaert
EPEls Van de Poel
Els Van de Poel
PJPhilippe G. Jorens
Philippe G. Jorens

14 October 2024 in Life
Verified
Journal Article
Open access
PDF file
RJRita Jacobs
Rita Jacobs
WVWalter Verbrugghe
Walter Verbrugghe
JBJason Bouziotis
Jason Bouziotis
IBIngrid Baar
Ingrid Baar
KDKarolien Dams
Karolien Dams
PJPhilippe G. Jorens
Philippe G. Jorens
(1) Background: Citrate is preferred in continuous renal replacement therapy (CRRT) for critically ill patients because it prolongs filter life and reduces bleeding risks compared to unfractionated heparin (UFH). However, regional citrate anticoagulation (RCA) can lead to acid–base disturbances, citrate accumulation, and overload. This study compares the safety and efficacy of citrate-based CRRT with UFH and no anticoagulation (NA) in acute kidney injury (AKI) patients. (2) Methods: A retrospective analysis was conducted on adult patients (≥18 years) who underwent CRRT from July 2010 to June 2021 in an intensive care unit. (3) Results: Among 829 AKI patients on CRRT: 552 received RCA, 232 UFH, and 45 NA. The RCA group had a longer filter lifespan compared to UFH and NA (56 h [IQR, 24–110] vs. 36.0 h [IQR, 17–63.5] vs. 22 h [IQR, 12–48]; all Padj < 0.001). Bleeding complications were fewer in the RCA group than in the UFH group (median 3 units [IQR, 2–7 units] vs. median 5 units [IQR, 2–12 units]; Padj < 0.001) and fewer in the NA group than in the UFH group (median 3 units [IQR, 1–5 units] vs. 5 units [IQR, 2–12 units]; Padj = 0.03). Metabolic alkalosis was more common in the RCA group (32.5%) compared to the UFH (16.2%) and NA (13.5%) groups, while metabolic acidosis persisted more in the UFH group and NA group (29.1% and 34.6%) by the end of therapy vs. the citrate group (16.8%). ICU mortality was lower in the RCA group (52.7%) compared to the UFH group (63.4%; Padj = 0.02) and NA group (77.8%; Padj = 0.003). (4) Conclusions: Citrate anticoagulation outperforms heparin-based and no anticoagulation in filter patency, potentially leading to better outcomes through improved therapy effectiveness and reduced transfusion needs. However, careful monitoring is crucial to limit potential complications attributable to its use.